10-Q: Strata Skin Sciences Reports First Quarter 2025 Results: Revenue Stable, Losses Narrow

Strata Skin Sciences' Q1 2025 results show stable revenue with a reduced net loss compared to the same period last year.

Summary

• Strata Skin Sciences, Inc. reported its financial results for the first quarter of 2025.
• Net revenue remained relatively stable at $6.812 million compared to $6.754 million in Q1 2024.
• The company experienced a net loss of $2.432 million, an improvement from the $3.368 million loss in the same period last year.
• The loss per share of common stock was $(0.58) compared to $(0.96) in the prior year.
• As of March 31, 2025, there were 846 XTRAC systems placed in dermatologists' offices in the United States under the recurring revenue model.
• The company had cash and cash equivalents of $6.512 million and restricted cash of $1.334 million as of March 31, 2025.
• The company believes its cash and cash equivalents, anticipated revenues, and operating expense management will be sufficient to satisfy its working capital needs for at least the next 12 months.
• The company is still dealing with the impact of the Russia-Ukraine war and the Middle East conflict on its supply chains and business.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still experiencing losses, they are narrowing, and gross profit is improving. The company also believes it has sufficient liquidity for the next 12 months. However, there are still significant risks and uncertainties facing the company.

Positives

• The company's net loss decreased significantly compared to the same period last year, indicating improved financial performance.
• Gross profit increased, both in absolute terms and as a percentage of revenues, driven by the use of refurbished parts and inventory write-offs.
• The company has a substantial number of XTRAC systems placed in dermatologists' offices, providing a recurring revenue stream.
• The company is actively working to increase awareness of XTRAC treatments through direct-to-patient advertising.
• The company believes it has sufficient liquidity to meet its obligations for the next 12 months.
• The company is managing its operating expenses effectively.

Negatives

• The company continues to experience net losses, although the losses are narrowing.
• The number of XTRAC systems placed in dermatologists' offices decreased slightly from 864 as of December 31, 2024 to 846 as of March 31, 2025.
• The company is facing challenges related to state sales and use tax matters, with ongoing audits and appeals.
• The company is still dealing with the impact of the Russia-Ukraine war and the Middle East conflict on its supply chains and business.
• The company has a material weakness in its internal control over financial reporting related to a lack of detailed management review of account reconciliations and account analyses, including those prepared by third-party specialists.

Risks

• Potential future pandemics, the Russia-Ukraine war, the Middle East conflict, and changes in U.S. trade policies could negatively impact the company's ability to access financing and on favorable terms.
• Supply chain disruptions and rising interest rates could affect the company's operations and financial performance.
• The company's ability to successfully defend itself in ongoing state sales and use tax audits is uncertain.
• The company's reliance on a limited number of customers poses a concentration risk.
• The company's ability to achieve future earnout and milestone payments related to the TheraClear acquisition is uncertain.
• Changes in the United States trade policy, including the impact of recently announced baseline tariffs, may have a material adverse effect on our business and results of operations.

Future Outlook

The company believes that its cash and cash equivalents, combined with anticipated revenues and operating expense management, will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments, and other liquidity requirements associated with its existing operations for at least the next 12 months.

Management Comments

• We reduced our direct-to-patient advertising over the course of 2023, which we believe contributed to a reduction in the number of XTRAC treatments compared to prior periods that continued into 2024.
• Therefore, our strategy going forward is to continue to increase our direct-to-patient program for XTRAC advertising in the United States, targeting psoriasis and vitiligo patients through a variety of media and through our use of social media such as Facebook and X (formerly Twit ter), and aimed at motivating them to seek out XTRAC treatments from our physician partners.

Industry Context

The medical technology industry is facing challenges due to the COVID-19 pandemic, supply chain disruptions, and geopolitical conflicts. Strata Skin Sciences is navigating these challenges by managing its expenses, diversifying its revenue streams, and focusing on its core products.

Comparison to Industry Standards

• It is difficult to compare Strata Skin Sciences directly to industry standards without specific competitor data.
• However, the company's focus on recurring revenue through its XTRAC system is a common strategy in the medical device industry.
• The company's efforts to expand its product portfolio with the TheraClear system are also in line with industry trends.
• The company's gross profit margin of 53.5% is within the typical range for medical device companies, but could be improved.
• The company's continued net losses are a concern, and it needs to demonstrate a path to profitability.

Legal Proceedings

• The states of New York and California have assessed the Company an aggregate of $5.2 million including penalties and interest related to state sales and use tax matters.
• The Company is in the administrative process of appeal with respect to the remaining $1.3 million of assessments in the State of New York.
• The Company is in the administrative process of appeal in California as well.

Stakeholder Impact

• Shareholders: The narrowing losses and improved gross profit are positive signs, but the company still needs to demonstrate a path to profitability.
• Employees: The company's ability to continue operations and invest in growth depends on its financial performance.
• Customers: The company's focus on improving awareness of XTRAC treatments could lead to increased demand and better access to care.
• Suppliers: The company's ability to meet its obligations depends on its financial performance and access to financing.
• Creditors: The company's compliance with covenants under its Senior Term Facility is important for maintaining access to financing.

Next Steps

• Continue to increase direct-to-patient advertising for XTRAC treatments.
• Monitor and manage the impact of geopolitical events on supply chains and business operations.
• Continue to improve processes and controls to remediate the material weakness in internal control over financial reporting.
• Continue to pursue the administrative process of appeal with respect to the remaining $1.3 million of assessments in the State of New York.

Key Dates

Keywords

XTRAC, TheraClear, dermatology, recurring revenue, excimer laser, financial results, Strata Skin Sciences, psoriasis, vitiligo, acne